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Vestibular migraine (VM) is one of the most common causes of episodic vertigo. We 
reviewed the results of multiple vestibular function tests in a cohort of VM patients who 
were diagnosed with VM according to the diagnostic criteria of the Barany Society and 
the International Headache Society and assessed the efficacy of each for predicting 
the prognosis in VM patients. A retrospective chart analysis was performed on 81 VM 
patients at a tertiary care center from June 2014 to July 2015. Patients were assessed 
by the video head impulse test (vHIT), caloric test, vestibular-evoked myogenic potentials 
(VEMPs), and sensory organization test (SOT) at the initial visit and then evaluated for 
symptomatic improvement after 6 months. Complete response (CR) was defined as no 
need for continued medication, partial response (PR) as improved symptoms but need 
for continued medication, and no response (NR) as no symptomatic improvement and 
requiring increased dosage or change in medications. At the initial evaluation, 9 of 81 
patients (11%) exhibited abnormal vHIT results, 14 of 73 (19%) exhibited abnormal caloric 
test results, 25 of 65 (38%) exhibited abnormal SOT results, 8 of 75 (11%) exhibited 
abnormal cervical VEMP results, and 20 of 75 (27%) exhibited abnormal ocular VEMP 
results. Six months later, 63 of 81 patients (78%) no longer required medication (CR), while 
18 (22%) still required medication, including 7 PR and 11 NR patients. Abnormal vHIT 
gain and abnormal caloric results were significantly related to the necessity for continued 
medication at 6-month follow-up (OR = 5.67 and 4.36, respectively). Abnormal vHIT and 
caloric test results revealed semicircular canal dysfunction in VM patients and predicted 
prolonged preventive medication requirement. These results suggest that peripheral 
vestibular abnormalities are closely related to the development of vertigo in VM patients.
Keywords: caloric test, head impulse test, prognosis, sensory organization test, vestibular-evoked myogenic 
potential, vestibular migraine
inTrODUcTiOn
Migraine is a common disorder characterized by recurrent throbbing headache, most often one-
sided, and it is occasionally preceded by aura. An association between vestibular dysfunction and 
migraine has been proposed and actively investigated (1–3). As a result of such studies, vestibular 
migraine (VM) is now widely accepted as a unique disease entity (4), although the pathophysiology 
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remains uncertain. VM presents as recurrent episodes of vertigo 
temporally related to migraine. The lifetime prevalence of VM 
was found to be approximately 1% in the German population (5). 
VM afflicts more people than other vertiginous disorders such 
as Meniere’s disease, vestibular neuritis, and benign paroxysmal 
positional vertigo (6).
There has been an effort to characterize the disease entity of 
VM and define the diagnostic criteria for it. Recently, the Barany 
Society and the International Headache Society released the 
diagnostic criteria of VM (4). According to it, VM patients should 
have at least five vestibular attacks. They should have history of 
migraine with or without aura and/or migraine features with at 
least 50% of the vestibular episodes. And the vestibular episodes 
cannot be better accounted for by another vestibular or ICHD 
diagnosis.
While some studies have assessed the results of vestibular 
function tests in VM patients (7–12), few have examined the 
associations between vestibular function test results and sub-
sequent symptomatic improvement on medication. One study 
revealed abnormal caloric test results in 22% of VM patients and 
video head impulse test (vHIT) abnormalities in 9% of patients 
(10), while another revealed abnormal caloric test results in 42% 
and abnormal vHIT results in 8% of VM patients (11).
In the present study, we analyzed the results of multiple 
vestibular function tests at baseline, caloric test, vHIT, vestibular-
evoked myogenic potential (VEMP), and sensory organization 
test (SOT) in VM patients and assessed the association of each 
with subsequent complete response (CR), partial response (PR), 
and no response (NR) to medication.
MaTerials anD MeThODs
Between June 2014 and July 2015, a retrospective chart review 
identified 81 VM patients according to the diagnostic criteria of 
the Barany Society and the International Headache Society (4). 
Patients were examined by the caloric test, vHIT, VEMP, and SOT 
at the initial visit.
Caloric test and SOT were performed in the same way as previ-
ous reports (11, 13). The bithermal caloric test was used, and eye 
movements were recorded by means of a video-based system (ICS 
water caloric stimulator NCI-480; Otometrics, Denmark). Each 
ear was irrigated with a constant flow of water at temperatures at 
30 and 44°C for 30 s. The maximum slow-phase eye velocities of 
the nystagmus were calculated after each irrigation session. The 
Jongkees formula was used to determine canal paresis, which 
was considered pathologic when it was 20% or more. SOT was 
conducted by means of a dynamic posturography (Equitest 
System; NeuroCom International, Inc., Clackamas, OR, USA). 
The SOT evaluates postural stability with systematic changes in 
visual and somatosensory information available to the patient 
and determines which sensory inputs (vestibular, visual, or 
somatosensory) the patient relies upon most to maintain postural 
stability. In SOT, a vestibular ratio (ratio of mean values condi-
tion 5/condition 1) and a composite score (a weighted average of 
the scores from the six conditions of the SOT) were analyzed in 
patients. They were considered abnormal, when lower than the 
age-specific normative data given by the CDP manufacturer.
Vestibular-evoked myogenic potentials were recorded in the 
sitting position, with the head rotated away from the stimulated 
side during recording. The surface electrodes were placed as fol-
lows: the active electrode was placed over the middle third of the 
sternocleidomastoid muscle, the reference electrode was placed 
on the upper sternum, and the ground electrode was placed on 
the forehead. VEMPs were elicited using 500-Hz Blackman tone 
pips with a 2-ms rise/fall time and 1-ms plateau presented at a 
rate of 9/s through insert earphones. The stimulus intensities were 
90-dB nHL, and the electromyography signal was amplified and 
bandpass filtered (30–1,500  Hz) using the GSI Audera system 
(Grason-Stadler, Eden Prairie, MN, USA). The results were con-
sidered pathological, if there was an interaural amplitude differ-
ence ratio greater than 40%, an interaural difference in threshold 
greater than 15 dB, or the absence of VEMP.
Video head impulse test (ICS Impulse, GN Otometrics, 
Taastrup, Denmark) was performed as described in a previous 
report (11). The vHIT gain was calculated as the ratio of the 
area under the curves of the eye to head movement, which was 
set by the device. A vHIT gain less than 0.8 in the lateral canal 
(LSCC) plane was considered abnormal. Gain asymmetry (GA) 
of the vHIT gains for head rotations to both sides were calculated 
using a general formula analogous to the formula for caloric 
canal paresis; GA = [(Gc − Gi)/(Gc + Gi)] × 100%, where Gc is 
the vHIT gain for head impulses exciting the contralateral canal 
and Gi is the vHIT gain for head impulses exciting the ipsilateral 
canal, which is the affected side. We defined abnormal GA ≥8.0% 
according to a previous study using normal subjects (14).
Our treatment protocol was as follows (13). Patients were 
advised to strictly adhere to a regular daily schedule with no caf-
feine and sufficient fluid intake. We also used a combination of 
Ginkgo biloba and antimigrainous preventive medications. The 
antimigrainous medications were administered using a three-
step regimen. At the initial visit, the calcium channel blocker 
flunarizine (5 mg/day) was prescribed as a first-line medication. 
The effects of this drug were evaluated on the next follow-up 
visit, which was usually 2–3 weeks after the initial visit, and the 
next step [continuous use, increased dosage (10  mg/day), or 
medication switch] was determined by the extent of symptom 
improvement or presence of side effects. Patients were followed 
up on a monthly basis thereafter. Amitriptyline, a tricyclic amine, 
was used as a second-line medication if there was no improve-
ment in symptoms or if side effects occurred with flunarizine. 
Amitriptyline was started at 10  mg/day, and the dosage was 
increased by 10–20 mg every month up to 90 mg/day until there 
was some improvement. Topiramate known as an anticonvulsant 
was administered as a third-line medication. The dosage started at 
25 mg/day and was increased by 25 mg every week to a maximum 
of 100 mg/day. Topiramate was taken for more than 2 months.
The patients were assessed for symptomatic improvement 
6  months after the initial visit. CR was defined as no need for 
continued medication, PR as improved symptoms but need for 
continued medication, and NR as no symptomatic improve-
ment, thereby requiring a dose increase or medication change. 
We analyzed the relationships between responsiveness to these 
preventive medications and the results of the initial vestibular 
function tests.
TaBle 1 | Demographic characteristics of patients according to the drug 
treatment response at 6-month follow-up.
Variables no medication 
required  
at 6-month FU
Medication  
required  
at 6-month FU
p-value
complete recovery 
(n = 63)
Partial recovery 
(n = 7)
no recovery 
(n = 11)
Sex, n (%) 0.496
Male 14 (74%) 1 (5%) 4 (21%)
Female 49 (79%) 6 (10%) 7 (11%)
Mean age 
(years)
51.4 48.9 49.7 0.899
FU, follow-up; CR, complete recovery 6 months after the initial visit; PR, partial 
recovery 6 months after the initial visit; NR, no recovery 6 months after the initial visit.
TaBle 3 | Prognostic factors affecting the necessity of medication in 
vestibular migraine patients.
Variables Or 95% ci for Or
lower Upper
Abnormal caloric test 4.364 1.268 15.013
Abnormal vHIT gain 5.673 1.337 24.075
OR, odds ratio; vHIT, video head impulse test.
TaBle 2 | results of vestibular function tests according to the drug 
treatment responses.
Vestibular function 
test
no medication  
required at  
6-month FU, n (%)
Medication  
required at  
6-month FU, n (%)
p-value
caloric test
Normal (n = 59) 48 (81%) 11 (19%) 0.014
Abnormal (n = 14) 7 (50%) 7 (50%)
vhiT gain
Normal (n = 72) 59 (82%) 13 (18%) 0.011
Abnormal (n = 9) 4 (44%) 5 (56%)
cs amplitudes in vhiT
Normal (n = 72) 58 (80.6%) 14 (19.4%) 0.089
Abnormal (n = 9) 5 (55.6%) 4 (44.4%)
Vestibular ratio in sOT
Normal (n = 40) 30 (75%) 10 (25%) 0.539
Abnormal (n = 25) 17 (68%) 8 (32%)
cVeMP
Normal (n = 67) 50 (74.6%) 17 (25.4%) 0.420
Abnormal (n = 8) 7 (87.5%) 1 (12.5%)
oVeMP
Normal (n = 55) 40 (72.7%) 15 (27.3%) 0.271
Abnormal (n = 20) 17 (85%) 3 (15%)
FU, follow-up examination; CS, catch-up saccades; cVEMP, cervical vestibular-evoked 
myogenic potential; oVEMP, ocular vestibular-evoked myogenic potential; vHIT, video 
head impulse test; SOT, sensory organization test.
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All statistical analyses were conducted using SPSS 18.0 (SPSS 
software, SPSS Inc., Chicago, IL, USA). The chi-square test was 
used to compare the abnormal rates (patients with abnormal 
results/total) of vestibular function tests between the CR and 
combined PR plus NR groups. We also performed univariate 
logistic regression analyses to calculate the odds ratios and the 
corresponding 95% confidence intervals (CIs).
This study protocol was approved by the Institutional Review 
Board of the Asan Medical Center.
resUlTs
Eighty-one VM patients were enrolled in this study (19 males, 62 
females; mean age 50.8 years, range 18–82 years; mean history of 
vertigo, 23 ± 34 months). There were no statistical differences in 
demographic features, including sex ratio and mean age, between 
the drug-responsive VM patient group (CR group) and partial/
non-responsive group (PR plus NR) (Table 1).
Table  2 shows the prevalence of each abnormal vestibular 
function test in both groups. At the initial evaluation, 9 of 81 
patients (11%) exhibited abnormal vHIT results, 14 of 73 (19%) 
exhibited abnormal caloric test results, 25 of 65 (38%) exhibited 
abnormal SOT results, 8 of 75 (11%) exhibited abnormal cervical 
VEMP (cVEMP) results, and 20 of 75 (27%) exhibited abnor-
mal ocular VEMP (oVEMP) results. The abnormal rates of the 
caloric test and vHIT gain significantly differed between groups 
(p < 0.05), while there was no significant group difference in the 
amplitude of catch-up saccades in vHIT, vestibular ratio in SOT, 
cVEMP responses, and oVEMP responses.
Six months later, 63 of 81 patients (78%) no longer required 
medication (CR), while 7 exhibited PR and 11 exhibited NR. 
Prevalences of abnormal vHIT gain and caloric test results were 
significantly related to the necessity for continued medication 
at the 6-month follow-up (OR  =  5.67 and 4.36, respectively, 
Table 3).
DiscUssiOn
Caloric stimulation is the most commonly used method to quan-
tify the function of the lateral semicircular canals and identify 
the side of peripheral vestibular dysfunction. Our previous study 
revealed abnormal canal paresis based on caloric test results in 
23% of VM patients (9). In the present study, 19% of VM patients 
exhibited abnormal caloric test results, within the range (8–25%) 
of previous studies (3, 7, 15, 16). vHIT assesses the function of the 
semicircular canals in response to high-frequency head move-
ment, which is more suitable for assessing real-world vestibular 
function of the canals than the caloric test. Abnormal vHIT was 
found in approximately 10% of VM patients in other studies 
(10,  11), similar to our present results (11%). A few posturo-
graphic studies have assessed VM patients. While posturography 
is not sufficient to diagnose VM, it can detect balance problems 
in some patients with a normal vestibule-ocular reflex (17). In the 
present study, a substantial minority of VM patients (38.5%) had 
abnormal SOT results, in accordance with the 45% prevalence 
in our previous study (9). cVEMP and oVEMP tests assess the 
otolith organs (saccule and utricle). Decreased amplitudes in 
the cVEMP test have been reported in VM patients (8, 18, 19). 
In addition, abnormal VEMP findings, including latency 
prolongation and shift to a preferred frequency to 1 kHz, have 
been reported in VM patients (20). cVEMP has recently been 
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proposed as a diagnostic tool for differentiating Meniere’s disease 
patients from VM patients using the 500-Hz asymmetry ratio and 
1,000/500-Hz frequency ratio (12).
What is the clinical significance of vestibular abnormalities in 
VM patients? In our study, neither cVEMP nor oVEMP could 
predict the drug response of VM patients. Similarly, SOT failed to 
predict the drug response of VM patients. Alternatively, vHIT and 
caloric test results were predictive of medication response. The 
vast majority (81%) of patients with normal caloric test results at 
the initial evaluation were complete responders, compared with 
only 50% of patients with abnormal caloric test results. Similarly, 
complete recovery was observed in 82% of patients with normal 
vHIT gain, which was significantly higher than that observed in 
patients with abnormal vHIT gain (44% patients). These statisti-
cally significant differences suggest that vestibular abnormalities 
are closely related to the medication responsiveness of VM 
patients. In VM patients with recurrent vertigo attacks for more 
than 6 months, poor response of vertigo symptoms to medication 
was related to the abnormal vestibular ratio of SOT (p = 0.011) 
(13). In this same study, there was a tendency for poor drug 
responsiveness in VM patients with abnormal caloric results 
(p = 0.055) (13).
There is no proven pathophysiology of VM, and the diagnosis 
of VM is based on clusters of specific symptoms and subject to 
speculation. Several hypotheses have been proposed to explain 
how migraine can occur with audiovestibular symptoms. VM 
may result from spreading depression affecting the brainstem 
(3). Alternatively, vasospasm of the internal auditory artery could 
lead to peripheral vestibular dysfunction and VM (21). Further, 
audiovestibular symptoms may arise by trigeminal neurogenic 
inflammation in the labyrinth, resulting in local plasma extrava-
sation, or through vasospasm of the internal auditory artery 
(22). It was reported that the lifetime prevalence of migraine 
was higher in Meniere’s disease group (56%) compared to con-
trols (25%), arguing a pathophysiologic link between the two 
diseases (23). Thus, the balance of evidence appears to support 
contributions of both peripheral and central vestibular deficits 
in VM pathogenesis. However, it may be argued that a vestibular 
abnormality is a coincidental finding, and it is possible that some 
patients with vestibular abnormalities that have been classified 
as VM may in fact have a different disorder. It has been reported 
that comorbid conditions (Meniere’s disease, benign paroxysmal 
positional vertigo, or chronic subjective dizziness) are important 
contributors to vestibular symptoms and that induced vertigo can 
act as a migraine trigger (16, 24, 25). The current definition of 
VM might include migraine that is coincided with or caused by 
vestibular disorders, which cannot be well categorized so far.
cOnclUsiOn
Abnormal results of vHIT and caloric tests, revealing semicircu-
lar canal dysfunction in VM patients, significantly reduced the 
probability of CR to preventive medications after 6  months of 
treatment, suggesting that peripheral vestibular abnormalities are 
closely related to the development of vertigo in VM patients.
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